US › Healthcare

AC Immune Ltd (ACIU)

US · Healthcare · Biotechnology

$2.68+1.13%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$15.1M

Revenue YoY

+1057.2%

Net profit

$1.9M

EPS

$0.03

EPS estimate

$-0.22

Net margin

12.4%

EPS came in at 0.03 against a street estimate of -0.22 — a beat of 113.6%.

Key statistics

Market cap

$264.5M

Forward P/E

16.2

P/B

6.32

Book value

$0.43

EPS (TTM)

$-0.52

52-week high

$4.00

52-week low

$2.10

50-day MA

$2.51

200-day MA

$2.83

Beta

1.59

Analyst view

Analysts rate AC Immune Ltd a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $8.50.

Shareholding

Insiders

37.90%

Institutions

24.45%

Largest institutional holders

Fund	Stake
Bvf Inc	19.94%
Wells Fargo & Co	1.01%
Millennium Management LLC	0.78%
Renaissance Technologies Corp	0.63%
BlackRock Inc	0.53%
Arrowstreet Capital Limited Partnership	0.41%
Dimensional Fund Advisors, Inc.	0.34%
Northern Trust Corp	0.28%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for AC Immune Ltd — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.